Full text
Earnings transcript
Read the complete earnings call transcript.
A
Agilent Technologies, Inc.
$135.14
-0.34
(-0.25%)
| Exchange: | NYSE |
| Market Cap: | 38.168B |
| Shares Outstanding: | 443.103M |
Delayed data
About The Company
| Sector: | Healthcare | |||||
| Industry: | Medical – Diagnostics & Research | |||||
| CEO: | Padraig McDonnell | |||||
| Full Time Employees: | 17900 | |||||
| Address: |
| |||||
| Website: | https://www.agilent.com |
Agilent Technologies, Inc. delivers specialized, application-focused technologies and services to the global life sciences, diagnostics, and applied chemistry industries. Its Life Sciences and Applied Markets segment provides a comprehensive portfolio of analytical instrumentation. This includes liquid chromatography (LC) and gas chromatography (GC) systems, often integrated with mass spectrometry (MS) for advanced analysis (LC-MS, GC-MS). They also offer inductively coupled plasma mass spectrometry (ICP-MS), atomic absorption (AA), microwave plasma-atomic emission spectrometry (MP-AES), and inductively coupled plasma optical emission spectrometry (ICP-OES) instruments, alongside Raman spectroscopy for material characterization. Beyond spectroscopy, the segment supplies cell analysis solutions such as plate-based assays, flow cytometers, real-time cell analyzers, imaging systems, and microplate readers. Complementing these are various laboratory software, information management platforms, data analytics tools, automated and robotic lab systems, dissolution testing equipment, vacuum technology, and general measurement solutions. The Diagnostics and Genomics division offers cutting-edge tools for genetic and diagnostic research. These encompass arrays designed for DNA mutation detection, genotyping, gene copy number determination, identification of gene rearrangements, DNA methylation profiling, and gene expression analysis. This segment also provides target enrichment solutions for next-generation sequencing, along with software for genetic data management and interpretation. Furthermore, it synthesizes custom oligonucleotides. Other significant offerings include immunohistochemistry (IHC), in situ hybridization (ISH), hematoxylin and eosin (H&E) staining, and specialized staining solutions. The division also supplies consumables and software essential for quality control analysis of nucleic acid samples, as well as reagents for turbidimetry and flow cytometry applications. A key area of development for this segment is liquid-based pharmacodiagnostics. Agilent CrossLab, the third segment, focuses on providing essential laboratory consumables and services. Its product range features GC and LC columns, products for sample preparation, custom chemical formulations, and various supplies for laboratory instruments. Complementary services include expert support for startup, ongoing operations, training, compliance, Software-as-a-Service (SaaS) offerings, asset management, and professional consultation. The company’s products reach customers through a diverse sales network, including direct sales teams, distributors, resellers, manufacturer’s representatives, and its e-commerce platforms. Agilent Technologies, Inc. was established in 1999 and maintains its corporate headquarters in Santa Clara, California.
Click to read more…
Revenue Segmentation
EPS
Historical EPS and analyst estimates in one chart. Log in for the full interactive view and links to detailed estimates.
Earnings Call
AI summary
Key takeaways
Short, structured highlights from the call so you can focus on what matters.
Log in to continue
Log in to read the full transcript and AI-generated earnings summaries.
Login — it's freeIncome Statement
| Year | 2023 | 2024 | 2025 |
|---|---|---|---|
| Revenue | 6,833,000 | 6,510,000 | 6,948,000 |
| Gross Profit | 3,465,000 | 3,535,000 | 3,643,000 |
| EBITDA | 1,703,000 | 1,874,000 | 1,835,000 |
| Operating Income | 1,350,000 | 1,488,000 | 1,479,000 |
| Net Income | 1,240,000 | 1,289,000 | 1,303,000 |
(* All numbers are in thousands)
Balance Sheet
| Year | 2023 | 2024 | 2025 |
|---|---|---|---|
| Total Assets | 10,763,000 | 11,846,000 | 12,727,000 |
| Total Liabilities | 4,918,000 | 5,948,000 | 5,986,000 |
| Total Stockholders Equity | 5,845,000 | 5,898,000 | 6,741,000 |
| Total Debt | 2,735,000 | 3,574,000 | 3,354,000 |
| Cash and Cash Equivalents | 1,590,000 | 1,329,000 | 1,789,000 |
(* All numbers are in thousands)
Cash Flow Statement
| Year | 2023 | 2024 | 2025 |
|---|---|---|---|
| Operating Cash Flow | 1,772,000 | 1,751,000 | 1,303,000 |
| Capital Expenditure | -298,000 | -378,000 | 0 |
| Free Cash Flow | 1,474,000 | 1,373,000 | 1,303,000 |
| Net Income | 1,240,000 | 1,289,000 | 36,000 |
| Net Change in Cash | 537,000 | -261,000 | 459,000 |
(* All numbers are in thousands)
Analyst Estimates
| Fiscal Year | 2030 | Full Access | Full Access | Full Access | Full Access |
|---|---|---|---|---|---|
| Estimated Revenue (Low) | 9,292,243.982 | Full Access | Full Access | Full Access | Full Access |
| Estimated Revenue (High) | 9,453,968.390 | Full Access | Full Access | Full Access | Full Access |
| Estimated Revenue (Avg) | 9,368,006.850 | Full Access | Full Access | Full Access | Full Access |
| Estimated Ebitda (Low) | 2,524,193.979 | Full Access | Full Access | Full Access | Full Access |
| Estimated Ebitda (High) | 2,568,125.647 | Full Access | Full Access | Full Access | Full Access |
| Estimated Ebitda (Avg) | 2,544,774.603 | Full Access | Full Access | Full Access | Full Access |
| Estimated Net Income (Low) | 2,477,167.288 | Full Access | Full Access | Full Access | Full Access |
| Estimated Net Income (High) | 2,533,351.008 | Full Access | Full Access | Full Access | Full Access |
| Estimated Net Income (Avg) | 2,503,488.408 | Full Access | Full Access | Full Access | Full Access |
| Estimated SGA Expense (Low) | 2,255,307.018 | Full Access | Full Access | Full Access | Full Access |
| Estimated SGA Expense (High) | 2,294,558.914 | Full Access | Full Access | Full Access | Full Access |
| Estimated SGA Expense (Avg) | 2,273,695.314 | Full Access | Full Access | Full Access | Full Access |
| Estimated EPS (Avg) | 8.820 | Full Access | Full Access | Full Access | Full Access |
| Estimated EPS (High) | 8.920 | Full Access | Full Access | Full Access | Full Access |
| Estimated EPS (Low) | 8.720 | Full Access | Full Access | Full Access | Full Access |
| Number of Analysts (Estimated Revenue) | 9 | Full Access | Full Access | Full Access | Full Access |
| Number of Analysts (Estimated EPS) | 2 | Full Access | Full Access | Full Access | Full Access |
Log in to continue
Log in and subscribe to Full Access to see up to 5 years of analyst estimates.
Login — it's free(* All numbers are in thousands)
Current Key Metrics
Log in to continue
Log in to see all key valuation metrics and ratios for this symbol.
Login — it's freeForward P/E Ratios
Log in to continue
Log in with Full Access for forward P/E high/low estimates and the full multi-year table.
Login — it's freeSWOT Analysis
At what price to buy it? -
Intrinsic Value Calculator
Based on current fundamentals and analyst forecasts, MARKETSnap estimates A intrinsic value between $52.60 – $69.43 per share. This depends on revenue growth, margins, and discount rate.
This is an automatic estimate. The most reliable way to know fair value for your own assumptions is to run the calculator below.
[intrinsic_calculator]
Common questions about A valuation
Is Agilent Technologies, Inc. (A) overvalued or undervalued right now?
MARKETSnap estimates intrinsic value for Agilent Technologies, Inc. (A) using its proprietary valuation methodology, which incorporates discounted cash flow (DCF) analysis together with long-term earnings and fundamentals assumptions. By comparing intrinsic value to the current market price, long-term investors can see whether the stock screens as potentially overvalued, fairly valued, or undervalued today.
Is A a buy, hold, or sell for long-term investors?
MARKETSnap does not give one-word “buy” or “sell” calls. Instead, it shows whether A trades at a premium or discount to its estimated intrinsic value, how sensitive that value is to growth and margin assumptions, and how the stock fits into a diversified, long-term portfolio so investors can make their own buy, hold, or sell decision.
What is A’s P/E ratio?
You can see A’s trailing P/E (TTM) and forward P/E estimates in the Current Key Metrics and Forward P/E Ratios sections above. The P/E ratio compares the current share price to earnings per share and helps investors gauge valuation relative to earnings.
How is intrinsic value calculated for A?
MARKETSnap uses its own valuation framework—not a generic spreadsheet DCF alone. Future cash flows and earnings are projected, discounted, and combined with MARKETSnap’s methodology so intrinsic value reflects fundamentals and long-term assumptions. You can run your own inputs and see the result using the Intrinsic Value Calculator above.
Is A a good long-term investment?
Whether A fits a long-term portfolio depends on your assumptions about growth, margins, and risk. MARKETSnap provides the metrics, intrinsic value calculator, and SWOT context so you can form your own view rather than rely on a single buy/sell rating.
A
1-day price chart preview. Log in for 1W through 5Y ranges and period tabs.
Daily snapshot
-0.25
Trading Metrics:
| Open: | 135.39 | Previous Close: | 135.48 | |
| Day Low: | 134.04 | Day High: | 135.87 | |
| Year Low: | 108.35 | Year High: | 160.27 | |
| Price Avg 50: | 118.64 | Price Avg 200: | 130.11 | |
| Volume: | 121855 | Average Volume: | 2.259M |
Log in to continue
Log in for multi-period charts (1W–5Y), period tabs, and the same layout as members.
Login — it's free
